NCT07589413Recruiting
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
A Predictive Model for Recurrence and Progression Risk After TURBT for Bladder Cancer on Intraoperative Irrigation Fluid Absorption Volume and Perioperative cfDNA Levels
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This prospective observational cohort study aims to evaluate the association between intraoperative irrigation fluid absorption and perioperative cell-free DNA (cfDNA) dynamics in patients undergoing transurethral resection of bladder tumor (TURBT). Eligible patients with suspected or confirmed bladder cancer scheduled for TURBT will be enrolled. Intraoperative irrigation fluid absorption volume will be recorded, and peripheral blood samples will be collected before surgery and within 24 hours after surgery for cfDNA extraction and mutation analysis. The study will assess whether irrigation fluid absorption volume is associated with changes in cfDNA concentration, tumor-related mutation detection, and clinicopathological features, including tumor stage, grade, size, number, invasion depth, concomitant carcinoma in situ, operative time, resection depth, and intraoperative blood loss. Patients will also be followed for postoperative recurrence, progression, metastasis, and other adverse oncological outcomes. This study may provide preliminary evidence for understanding perioperative tumor-related molecular changes during TURBT and may help improve risk stratification, perioperative management, and postoperative follow-up strategies for patients with bladder cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 1 May 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Zhiping Wang
- Diseases
- Bladder cancer
- NCT number
- NCT07589413
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Apr 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radical cystectomy or systemic antitumor therapy before enrollment.
Other illness
- Non-urothelial bladder malignancy confirmed by pathology.
- History of other malignant tumors within the past 5 years, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
- Serious uncontrolled intercurrent illness that may interfere with study participation, follow-up, or compliance, including active infection, symptomatic congestive heart failure, unstable angina, clinically significant arrhythmia, severe psychiatric illness, or other conditions judged by the investigator to make participation unsuitable.
Other
- Inadequate blood sample quality or insufficient DNA yield for mutation analysis.
- Pregnancy or breastfeeding.
Who the study is looking for
- Age 18 years or older.
- Suspected or histologically confirmed urothelial carcinoma of the bladder.
- Scheduled to undergo TURBT.
- Availability of sufficient peripheral blood samples for cfDNA extraction and mutation analysis.
- Availability of complete clinicopathological and perioperative data.
- Ability to provide informed consent and comply with study follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Second Hospital of Lanzhou University Coordinator of this site? Confirm its status | Lanzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.